Articles
Page 14 of 23
-
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A103
-
The role of particulate guanylyl cyclase B (GC-B) in auditory function in adult mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A102 -
Interaction of cCMP with the cGK, cAK and MAPK kinases in murine tissues
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A101 -
Real-time imaging of cGMP signals in platelets
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A98 -
Identification of new inhibitors of soluble guanylyl cyclase activity
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A95 -
Linaclotide-induced electrolyte secretion in human and rat colon: Ussing chamber studies
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A94 -
Influence of smoking on vascular reactivity to cGMP generators in human internal thoracic arteries
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A93 -
Direct visualization of cGMP microdomains in adult cardiomyocytes
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A91 -
Effect of soluble guanylyl cyclase activator and stimulator therapy on nitroglycerin-induced nitrate tolerance in rats
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A90 -
IWP-121: a novel sGC stimulator that reduces blood pressure and exhibits anti-fibrotic and anti-inflammatory activities in the Dahl Salt-Sensitive rat model
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A86 -
Functions of NO-GC1 and NO-GC2 in pain processing
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A74 -
The world's first clinical randomized trial of atrial natriuretic peptide for preventing cancer recurrence following lung cancer surgery
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A72 -
Natriuretic peptides regulate sympathetic nervous activity independent of mineralocorticoid receptor
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A71 -
Contribution of the NO-GC isoforms to airway responsiveness
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A67 -
Enhancement of cAMP-mediated inotropic responses by CNP is regulated differently by PDE2 in normal and failing hearts
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A66 -
Correlation of vascular smooth muscle cell phenotype and cGMP signalling
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A63 -
CNP attenuates renal toxicity induced by cisplatin in murine kidney
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A61 -
Cyclic GMP Dependent Protein Kinase (PKG) as a mediator of EGFR-Induced Apoptosis in Breast Cancer
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A60 -
Discovery of IWP-051, a Novel Orally Bioavailable Soluble Guanylate Cyclase Stimulator with Sustained and Dose-Dependent Hemodynamic Effects
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A59 -
The sGC-stimulator Riociguat for the treatment of Raynaud's phenomenon: A single-dose, double-blind, randomized, placebo-controlled cross-over study (DIGIT)
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A58 -
The sGC stimulator BAY 41-8543 in a rat model of hypertension-induced heart failure
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A57 -
Cell-specific modulation of gastrointestinal NO-induced relaxation by phosphodiesterases
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A56 -
NO-dependent cGMP signalling in neurons and astrocytes
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A55 -
Concomitant administration of sGC stimulators with common classes of anti-hypertensive agents results in increased efficacy in spontaneously hypertensive rats
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A54 -
Erythrocytes do not produce biologically active NO
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A53 -
A CNP-cGMP-cGKI-MAPK pathway promotes melanoma growth in vitro and in vivo in mice
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A49 -
A systems biology approach to cGMP suggests a prominent role for sGC in stroke: Validation by mechanism-based activation of apo-sGC in non-steal dosing coveys neuroprotection and increased survival
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A39 -
Inhaled Nitric Oxide: an sGC-dependent IOP lowering agent
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A38 -
Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated with Reduced NT-proANP, Increased Stroke and Higher Diastolic Blood Pressure
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A37 -
Anemia of cGKI deficient mice is caused by intestinal bleeding
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A35 -
Investigation of the role of multidrug resistance proteins (MRPs) in vascular homeostasis
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A33 -
Computational exploration of the binding mode of the heme-dependent activator YC-1 into the active catalytic site of soluble guanylate cyclase
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A32 -
Hormone suppression silencing GUCY2C is required for colorectal cancer
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A31 -
Pivotal vascular homeostatic role for endothelium-derived C-type natriuretic peptide (CNP)
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A27 -
sGC redox regulation and asthma
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A26 -
The cyclic nucleotide 3’,5’-cIMP produced by sGC is a second messenger in the vascular wall
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A25 -
Antifibrotic function of cGKI in the kidney
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A23 -
Novel roles of cardiac natriuretic peptides in renal compensatory hypertrophy
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A22 -
Mechanism and protective properties of S-nitrosation by nitric oxide in cardiac mitochondria
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A21 -
Ultrasensitive signal detection by a guanylyl cyclase chemoreceptor
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A20 -
Inhibition of cGMP-metabolizing PDEs as target for cognitive enhancement
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A19 -
Targeting cyclic nucleotides in CNS drug discovery: a translational approach into cognition enhancement
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A18 -
New insights into leveraging PKG signalling to treat diseased hearts
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A17 -
cGMP and cAMP pathways rearrange ARHGAP17 and ARHGEF6 protein complexes to control Rac1 in platelets
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A16 -
Roles of 8-nitro-cGMP in autophagy regulation
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A14 -
Gene therapy approaches to restore retinal cGMP channel function
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A9 -
Natriuretic peptides and cGMP in metabolic disease
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A7 -
The discovery and characterization of novel soluble guanylate cyclase stimulators
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A5 -
MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A3 -
The clinical development of sGC modulators, riociguat and vericiguat
Citation: BMC Pharmacology and Toxicology 2015 16(Suppl 1):A2
Annual Journal Metrics
-
Citation Impact
2.605 - 2-year Impact Factor (2021)
2.943 - 5-year Impact Factor (2021)
0.953 - SNIP (Source Normalized Impact per Paper)
0.497 - SJR (SCImago Journal Rank)Speed
48 days to first decision for all manuscripts (Median)
64 days to first decision for reviewed manuscripts only (Median)Usage
642,939 Downloads (2022)
402 Altmetric mentions (2021)
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication